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Fetal/neonatal  exposure  to the  endocrine  disruptor  bisphenol  A  (BPA)  has induced  obe-
sity  and  increased  glucose  intolerance.  We  hypothesized  that  chronic  BPA  exposure  would
worsen the  obesity  and glucose  intolerance  induced  by a  high  fat diet  (HFD).  The  drinking
water of  C57bl/6n  dams  was  treated  with  vehicle  (VEH)  or  BPA  (25 ng/ml)  from  gestation
day  11.5  to postnatal  day  21.  Another  group  was  treated  with  oral  diethylstilbestrol  (DES,
1  g/kg/day)  during  gestation.  Progeny  were  treated  with  VEH  (VEH  and  DES  groups)  or
BPA (2.5  ng/ml)  in  the  drinking  water  and  fed  either  a control  diet  (CD)  or HFD  from  weaning
until  euthanasia  at  4 months  of age. CD-fed  mice  were  similar  in  size;  however  HFD-BPA
males  and HFD-DES  mice  were  smaller  than  HFD-VEH  mice.  No  CD-fed  mice  were  glucose
intolerant.  All HFD-fed  mice  were  glucose  intolerant.  Cholesterol  and  triglyceride  were
increased  in  HFD-VEH  mice  and  HFD-BPA  males.  Total  fat weight  and  adipocyte  area  were
similar in HFD-VEH  and  HFD-BPA  mice  and  reduced  in  HFD-DES  mice.  HFD-BPA  females
increased  perirenal  and  reduced  gonadal  fat weights.  Reduced  leptin  and  increased  IL-6  in
CD-BPA and  CD-DES  mice  were  not  found  in  their  HFD-cohorts.  Adiponectin  levels  were
similar.  Thus,  although  chronic  BPA  exposure  did  not  increase  body  size  or increase  glucose
intolerance,  it induced  an adipokine  imbalance  in  CD-fed  mice  and  sex-speciﬁcally  altered
the lipid  response  and  adipose  deposition  when  fed  the  HFD.
© 2014  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is  an  open  access  article  under
Y-NC-Nthe CC  BAbbreviations: AUC, area under the curve; BL, body length; BPA,
bisphenol A; BMI, body mass index; BSA, body surface area; BW,  body
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glucose tolerance test; HFD, high fat diet; IL-6, interleukin 6; VEH, vehicle.
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1. Introduction
Exposure to various man-made compounds is contin-
uous, widespread and begins early in life [1–3]. National
surveys have demonstrated the near ubiquitous presence
of  many compounds, including the estrogenic endocrine
disruptor compound bisphenol A (BPA), in the urinary pro-
ﬁles  of most people [3–5]. Exposure to endocrine disruptor
compounds especially in early life stages may have long
term  consequences beyond their impact on reproductive
health. Although a link between higher BPA exposures
and greater chronic disease incidence has been challenged
[6], most epidemiological analyses suggest that higher
cess article under the CC BY-NC-ND license (http://creativecommons.org/
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At euthanasia, the weight of the testes, all prostate lobes,
seminal vesicles including contents, uterus and ovariesB.B. Patel et al. / Toxico
PA exposure may  enhance cardiovascular disease, obe-
ity  and diabetes morbidity in humans [7–11]. The impact
f  BPA might also be found before adulthood. Higher uri-
ary  BPA levels were linked to greater obesity in children
12,13]. One major concern is that increased exposure to
ndocrine disruptor compounds such as BPA may  be driv-
ng  an increase in obesity and type 2 diabetes in children
nd adults [3,14].
Supporting the human data, BPA exposure during the
etal/neonatal period has led to glucose intolerance in
he  adult progeny in most rodent studies [15–19]. When
dult  male and female rats and mice were compared,
PA exposed males showed glucose intolerance, while
imilarly treated females were unaffected [15–17]. How-
ver,  other studies did not ﬁnd a correlation between
arly life BPA exposure and glucose intolerance in adults
f  either sex [20,21]. BPA exposure is not restricted
o gestation or lactation; rather BPA exposure is life-
ong [3]. Thus, it was intriguing that glucose intolerance
as not observed in adult male or female outbred CD-
 mice treated with dietary from gestation day 0 until
uthanasia on postnatal day 70 [22]. Overall, such data
rgue  that the development of adult glucose intolerance
s greatly inﬂuenced by sex and the time of BPA expo-
ure.
Obesity is associated with the development of glu-
ose intolerance and type 2 diabetes [23]. In rodent
odels, studies linking BPA exposure with induced obe-
ity  and greater glucose intolerance have resulted in
onﬂicting results. A correlation between BPA-induced
besity and glucose intolerance in the adult progeny was
dentiﬁed in some, but not all, epidemiological studies
15,19–22,24–26]. In experimental studies, obesity can be
nduced  by feeding mice a diet high in fat. When out-
red CD-1 mice were exposed to low dose BPA during the
etal/neonatal period and then fed a control diet or high
at  diet for 5 weeks beginning at 9 weeks of age, no glucose
ntolerance was observed in male or female mice fed either
iet  [20]. In contrast, using a similar design and outbred
D-1 mice, but initiating control or high fat diet feeding
t  3 months of age, glucose intolerance was found in BPA
xposed males fed the control and high fat diets, but not
n  the similarly exposed and fed females [16]. Although
hese data found no consensus for an additional impact of
 high fed diet on mice exposed to BPA, they suggest the
otential for an additive effect for high fat diet and BPA
nd  suggest that male mice may  be especially suscepti-
le.
In  the present experiments, we extended these studies
o  a common inbred mouse line, C57bl/6n, and contin-
ously treated the mice with oral BPA from gestation
ay 11.5 to euthanasia at 4 months of age. We tested
he hypothesis that chronic BPA exposure would worsen
he  impact of obesity started in early life due to high
at feeding and that males would be particularly vul-
erable to the combined effect of BPA and a high fat
iet. We  report the impact of chronic BPA exposure on
ody  growth, organ fat deposits, mesenteric adipocyte
ize, glucose tolerance, serum lipid and adipokine param-
ters  of male and female mice fed a control or high fat
iet.orts 1 (2014) 522–532 523
2.  Materials and methods
2.1.  Animal manipulation
The  animal use protocol was reviewed by the Lady Davis
Institute Animal Care Committee and animal experiments
were performed according to the guidelines of the Cana-
dian  Council on Animal Care. The timeline of experimental
handling is shown in the schematic in Fig. 1A. C57bl/6n
female mice (Charles River, St. Constant, Que.) were mated
and  the day of vaginal plug detection designated gestation
day  0.5. Dams were fed a Harlan Teklad Global 2018 diet
(3.1  kcal/g, 6.2% fat, 18% calories fat) before mating and
during gestation and lactation. All mice were housed in
polycarbonate cages with ¼ in. corn cob bedding in a 12 h
dark/light  schedule. Food and water intake was  ad libitum.
BPA  (>99% pure, 2396558, CAS 80-05-7) was  purchased
from Sigma–Aldrich (Oakville, Ont.). BPA was dissolved
in ethanol and added to a concentration of 25 ng BPA/ml
sterile-ﬁltered drinking water. This amount replicates that
used  in previous studies that demonstrated BPA-mediated
glucose intolerance in outbred CD-1 mice [19,22]. An equal
volume  of ethanol (ﬁnal concentration 0.1%) was added to
the  drinking water of vehicle (VEH) treated dams and their
progeny.  Dams, n = 6–7/group, were exposed to the treat-
ments in glass bottles from gestation day 11.5 until pup
weaning on postnatal day 21.
Diethylstilbestrol (DES), a non-steroidal estrogen, has
been  used as an estrogenic reference compound for BPA
[27]  and in studies exploring the impact of endocrine
disruptor compounds in rodents [16,20,27–32]. DES
(99% pure, D4628, CAS 56-53-1) was  purchased from
Sigma–Aldrich (Oakville, Ont.). Dams, n = 6, were treated
once daily with DES (1.0 g/kg body weight in peanut
oil) on gestation days 11.5–14.5 using a micropipette. This
amount  is similar to that which previously induced glucose
intolerance in outbred CD-1 mice [19].
At weaning on postnatal day 21, 1–2 progeny from each
dam  were randomly selected to be placed on either a CD
(Teklad  TD6416, 3.7 kcal/g, 4.2% fat, 10% of calories from
fat)  or a HFD (Teklad TD6414, 5.1 kcal/g, 34% fat, 60% calo-
ries  from fat) until euthanasia at 4 months of age. Within
treatment groups, the BW of those selected for the CD or
HFD  were not statistically different. Also at weaning, the
concentration of BPA in the water was reduced ten-fold to
2.5  ng BPA/ml. The dose of BPA was  reduced at weaning
to simulate reduced BPA exposure in adulthood [3] and is
similar  to the exposures used in previous studies [16,20].
Mice,  n = 7–8/treatment/sex, were randomly selected for
each  test unless otherwise noted.
2.2. Physiological parameters
Body  weight (BW) and body length (BL) measurements
were collected at weaning on postnatal day 21 and monthly
thereafter until euthanasia at 4 months of age. BL was mea-
sured  from nose to anus using calipers.were measured. In addition, the BW,  BL and the wet weight
of  adipose deposits surrounding the kidneys, testes, ovaries
524 B.B. Patel et al. / Toxicology Reports 1 (2014) 522–532
Fig. 1. (A) Schematic of experimental design. C57bl/6n dams, n = 6–7 per treatment, were given drinking water containing BPA, 25 ng/ml, or an equal volume
of  ethanol (vehicle, VEH) beginning on gestation day 11.5 and continuing until weaning on postnatal day 21. The drinking water of progeny contained
2.5  ng/ml BPA beginning at weaning until euthanasia at 4 months of age. A separate group of dams were orally treated with DES (1 g/kg/day) using a
micropipette  on gestation days 11.5–14.5. VEH, BPA and DES progeny were randomly selected and fed either a control (CD) or high fat diet (HFD) from
weaning  until euthanasia. (B–D) Physiological parameters at weaning (B) or with time on diets in male (C) and female (D) mice. BL is body length in cm;
I  = [BW
 mean ±
BW  is body weight in grams; BMI  is body mass index using the formula BM
calculated  using the formula BSA =
[
K × 3
√
W2
]
). Data are expressed as
and mesentery was collected. Body mass index (BMI) was
calculated using the formula BMI  = [BW/(BL)2] × 100 where
BW  is in grams and BL in cm.  Body surface area (BSA) was
calculated using the formula BSA =
[
K × 3
√
W2
]
where K
is 10.5 and W is the BW in grams [33,34].2.3. Glucose and insulin tolerance tests
At ∼15 weeks of age, after 12 weeks on the respec-
tive diets, food was removed from the cages for 5 h/(BL)2] x 100 where BW is in g and BL in cm.  Body surface area (BSA) was
 SEM. Signiﬁcance indicated by p < 0.05 when compared with * VEH; † CD.
prior  to glucose tolerance testing [35]. Blood was col-
lected from the saphenous vein, applied to OneTouch
Ultra Test Strips and glucose levels read using a One-
Touch SureStep Glucometer (DiabetesShop, Brampton,
Ont.) according to the manufacturer’s instructions. After
baseline glucose measurement, mice were injected IP
with  dextrose (2.0 g/kg BW)  and glucose was quanti-
ﬁed 15, 30, 60 and 120 min  later. The area under the
curve (AUC) was  calculated using the trapezoidal rule
[35].
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.4. Serum analyses
Blood  was collected by cardiac puncture after a 4 h
ast.  The blood was allowed to clot, the serum collected
nd frozen at −80 ◦C prior to analyses. Measurement of
holesterol and triglyceride was performed by the McGill
omparative Medicine Department (Montreal, Que.) using
 VITROS 350 chemistry analysis system. ELISA kits spe-
iﬁc  for mouse serum samples were used to measure
eptin and adiponectin (ALPCO Diagnostics, Salem, NH)
nd  interleukin 6 (IL-6) (eBioscience, Inc., San Diego, CA)
sing  standard curves and according to the manufacturer’s
nstructions.
.5. Mesenteric adipocyte area measurement
A portion of the mesenteric fat collected at euthana-
ia from VEH, BPA and DES treated mice fed the HFD
as ﬁxed immediately in 4% formaldehyde. Tissue from
 = 4 mice/group was cryoprotected in 30% sucrose in PBS
vernight, equilibrated in PBS for ∼4 h and then frozen in
CT  (Tissue Tek, Torrance, CA) overnight at −20 ◦C. Sec-
ions, 5 m,  were cut using a cryostat at −24 ◦C and stained
ith Oil Red O [36]. Photographs were taken of 5 random
elds/section using Inﬁnity Capture software (Lumenera,
ttawa, Ont.). The outline of at least 100 fat cells/mouse
as measured using Image J software. The cross-sectional
rea of VEH male mice adipocytes was arbitrarily desig-
ated  100%.
.6.  Statistical analyses
The  Kolmogorov–Smirnov test was used to verify that
he  data had equal variance about the group mean prior to
NOVA  analyses. Signiﬁcance for all parameters was  eval-
ated  using two-way ANOVA with the statistical program
igmaStat 3.1 and the Student–Newman–Keuls post hoc
est.  Physiology parameters were tested for statistical sig-
iﬁcance  using ANCOVA and litter size as a covariate and
he  SPSS version 20 Statistical package. A p-value of <0.05
as  considered signiﬁcant.
.  Results
.1. BPA exposure and growth
To  mimic  continuous human BPA exposure via the oral
oute  and to approximate the higher BPA exposure of chil-
ren  and adolescents versus the lower exposure of adults
2,3],  we added BPA to the drinking water and treated
he mice with a higher dose of BPA during gestation and
actation, followed by a lower dose after weaning. Dams
eighed ∼22 g at mating and had increased body weight
BW) to ∼25 g by gestation day 11.5. Calculating an aver-
ge  water intake of 5 ml/day/25 g mouse [37], we estimate
hat  dams were exposed to 5 g/kg/day BPA at the begin-
ing  of treatment. The number of pups weaned from VEH
8.3  ± 0.7), BPA (8.0 ± 1.1) or DES (8.2 ± 0.4) dams was  sim-
lar  suggesting that neither BPA nor DES treatment had an
mpact  on pregnancy maintenance.orts 1 (2014) 522–532 525
Previous studies with early life exposure to BPA or DES
reported an increase in body size at weaning [26,38]. To
verify  that our treatments increased body size at weaning,
we  measured BW and body length (BL), and calculated body
mass  index (BMI) and body surface area (BSA), Fig. 1B. We
found  weanling male pups from BPA dams had increased
body size with increased BW,  BL and BSA. Female pups from
BPA  dams were longer than VEH female pups. Male and
female pups from DES dams were longer and male pups had
a  greater BSA than pups from VEH dams. Thus, as expected
[26], exposure to BPA and DES alone increased weanling
body size.
To  test whether chronic exposure to BPA altered body
growth with time and whether increased dietary fat imme-
diately  after weaning would alter the growth trajectory, we
changed  the diet of the mice at weaning on post-natal day
21  to one containing either 10% kcal or 60% kcal from fat.
At  this time, we  also reduced the amount of BPA in the
drinking water 10-fold for reasons described earlier. We
measured BW and BL, and calculated BMI  and BSA in males
and  females on each of the diets, Fig. 1C and D. Water intake
is  a function of BW in mice, including C57bl/6 mice [37]. We
measured  BW at the 4-, 8- and 12-week intervals in mice
fed  the CD and HFD and calculated water intake. Based
on  the predicted water intake predicted by their mea-
sured BW,  we estimate that male progeny fed the CD were
exposed  to 0.66 ± 0.1, 0.61 ± 0.1 and 0.59 ± 0.1 g/kg/day
BPA, and that female progeny fed the CD were exposed to
0.75  ± 0.1, 0.67 ± 0.1 and 0.65 ± 0.1 g/kg/day BPA at the
end  of the 4-, 8- and 12-week intervals, respectively. Sim-
ilarly,  we  estimate that male progeny fed the HFD were
exposed to 0.58 ± 0.1, 0.51 ± 0.1 and 0.49 ± 0.1 g/kg/day
BPA, and female progeny fed the HFD exposed to 0.66 ± 0.1,
0.59  ± 0.1 and 0.53 ± 0.1 g/kg/day BPA at the end of the
4-,  8- and 12-week intervals, respectively. These doses
approximate human exposure levels [39] and are similar
to  doses used previously to assess the impact of BPA on
glucose tolerance in CD-1 mice [16,19,20,22].
Body size increased similarly with time in VEH, BPA and
DES  males fed the CD, Fig. 1C. In female mice, CD-VEH and
CD-BPA  females grew similarly, Fig. 1D. The body length
(BL)  of CD-DES females was  longer and this group had
a  greater BSA at early times than CD-VEH females. HFD-
fed  mice increased body size with time in all mice when
compared with their CD-fed cohort. HFD-BPA males had
reduced  BW,  BMI  and BSA when compared with HFD-VEH
males by 12 weeks fed the HFD. In contrast, female growth
was  unaffected by BPA exposure and HFD-VEH and HFD-
BPA  females had similar body size parameters. HFD-DES
male and females had reduced BW,  BMI  and BSA than HFD-
VEH  males and females by 12 weeks fed the HFD. Overall,
BPA  exposure did not change growth when fed the CD, and
reduced  body growth in males fed the HFD.
To conﬁrm that sufﬁcient BPA was  ingested to induce
predicted changes in reproductive organ weights, we mea-
sured  prostate weight at euthanasia. CD-BPA males had
signiﬁcantly increased prostate weight when compared
with CD-VEH males, 61.2 ± 9 versus 35.1 ± 3.1, respec-
tively. As expected, prostate weight in CD-DES males,
36.3 ± 6, was  similar to that of CD-VEH males [40,41].
Testes, seminal vesicles, ovary and uterus weights did not
logy Reports 1 (2014) 522–532
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differ in VEH, BPA or DES treated mice. These data support
the  idea that the BPA treatment was sufﬁcient to induce a
well  established effect on prostate tissue [42].
3.2. Serum lipids
To  verify expected increases in cholesterol and trigly-
cerides upon HFD feeding in VEH mice and to determine
whether BPA and DES altered the lipid response to the diet,
we  measured circulating total cholesterol and triglyceride
in  serum samples collected at euthanasia, Table 1. In CD-
fed  mice, serum cholesterol was reduced in CD-BPA males
and  increased in CD-BPA females when compared with
CD-VEH mice. Serum cholesterol and triglyceride were
increased in HFD-VEH males and females versus their CD-
fed  cohorts suggesting that the HFD induced a predicted
increase in serum lipids. HFD-BPA males had increased
cholesterol and triglycerides when compared with their
CD-fed  cohorts, suggesting that BPA did not ablate the
lipid  response to a high fat diet in males. HFD-DES males
increased cholesterol only when compared with their
CD-DES cohort. In females, although HFD-VEH females
increased cholesterol and triglycerides, HFD-BPA females
had  reduced cholesterol and unchanged triglyceride when
compared with CD-BPA females. Also unlike VEH females,
HFD-DES females did not increase cholesterol or triglyce-
rides when compared with CD-DES females. Thus, BPA and
DES  exposures sex-speciﬁcally altered the levels of circu-
lating  cholesterol and triglycerides in response to control
and  high fat diet fed mice.
3.3.  Glucose homeostasis
To  determine whether continued BPA exposure would
impact glucose regulation and whether a HFD would reveal
additional glucose homeostasis abnormalities, we  mea-
sured  glucose levels at baseline and after glucose challenge
(GTT) in mice fed the CD and HFD. VEH, BPA and DES
mice fed the CD had similar baseline glucose levels within
the  male group and within the female group, Fig. 2A. All
HFD-fed mice had signiﬁcantly increased baseline glucose
compared with their CD-fed cohort. HFD-DES males had
a  lower baseline glucose level than HFD-VEH males. When
males  and females were compared, HFD-VEH and HFD-BPA
females, but not HFD-DES females, had lower baseline glu-
cose  than similarly treated males. Overall, BPA and DES
exposure did not increase baseline glucose in mice fed a
HFD.
CD-VEH  and CD-BPA males responded similarly to GTT,
Fig.  2B. CD-DES males had lower glucose at early times
than CD-VEH males. No differences were detected in CD-
fed  females, regardless of treatment. All HFD-fed mice were
more  glucose intolerant than their CD cohort. When the
AUC  was calculated for each time period, HFD-BPA females
had  a minor, but signiﬁcant, increase in AUC in the last hour
of  the GTT than HFD-VEH females, Fig. 2C. Thus, BPA had
no  impact on glucose intolerance in males or females when
fed  the CD whereas DES induced an improved glucose tol-
erance  in CD-fed males. We  conclude that continued BPA Ta
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Fig. 2. (A) Fasting glucose. Food was removed for 5 h and serum glucose was measured in n = 5–7 mice/group. (B and C) Glucose tolerance test and area
u se was 
m eriod. Da
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mnder  the curve calculation in male (B) and female (C) mice. Serum gluco
ice/group.  The total area under the curve was  calculated for each time p
ompared  with * VEH; † CD, ‡ males.
xposure induced a minor reduction in glucose tolerance
nd  only at a late time in HFD-fed females.
.4. Impact of BPA on adipose tissues
To test whether continued BPA exposure would alter
dipose deposition, we weighed total adipose tissue sur-
ounding the mesentery, kidneys and gonads, and indexed
otal  fat to BW (total fat/BW), Fig. 3. Total fat and total
at/BW were similar in CD-fed mice, regardless of treat-
ent,  Fig. 3A. HFD feeding increased total fat and total
at/BW in all mice when compared with their CD-fed
ohorts. Within the HFD groups, HFD-DES males had lower
otal  fat and reduced indexed total fat compared with HFD-
EH  mice. Therefore, chronic BPA exposure did not increase
otal  fat accumulation and DES exposure reduced total fat
ccumulation.
The  amount of fat surrounding the mesentery, perirenal
at  surrounding both kidneys, and gonadal fat surround-
ng both testes and both ovaries was measured to identify
hether the site speciﬁc organ fat deposition was altered
y  BPA, Fig. 3B. CD-fed males and females had similar
esenteric, perirenal and gonadal fat weights, regardlessmeasured at the times indicated after an IP injection of dextrose in n = 7
ta are expressed as mean ± SEM. Signiﬁcance, indicated by p < 0.05 when
of  treatment. HFD feeding increased fat weight at all sites
examined over that present in their CD-fed cohorts. How-
ever,  whereas HFD-VEH and HFD-BPA males had similar fat
weights,  HFD-DES males had reduced mesenteric, perire-
nal  and gonadal fat. All HFD females had similar amounts
of  mesenteric fat, regardless of drug treatment. HFD-BPA
females had increased perirenal fat compared with HFD-
VEH  females. In contrast, gonadal fat was  reduced in
HFD-BPA and HFD-DES females compared with HFD-VEH
mice. We  conclude that BPA and DES sex speciﬁcally altered
organ  fat deposition.
To  determine whether mesenteric fat adipocyte size
was  altered by BPA, we measured the area of Oil Red O
stained mesenteric adipocytes in HFD-fed mice, Fig. 4A.
We  found the mesenteric fat adipocyte area of HFD-VEH
and HFD-BPA males was similar whereas it was  reduced
signiﬁcantly in HFD-DES males, Fig. 4B. There were no dif-
ferences  in adipocyte size in female mice. Thus, BPA did
not  increase the mesenteric fat weight or adipocyte area in
males  or females. Both mesenteric fat weight and adipocyte
area  were reduced in HFD-DES males.
Increased fat may  be accompanied by increased
secretion of inﬂammatory cytokines [43]. To test
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Fig. 3. Mesenteric, perirenal and gonadal fat deposits in n = 6–8 mice/group were weighed. (A) Total weight of the fat deposits (left) and total fat indexed
to  BW (right). (B) Individual fat deposit weights. Data are expressed as mean ± SEM. Signiﬁcance, indicated by p < 0.05 when compared with * VEH; † CD, ‡
males.
 with Oi
sured in
en compFig. 4. (A) Sections of mesenteric fat isolated from HFD mice were stained
at  100× magniﬁcation. (B) The area of 100 adipocytes per mouse was  mea
Data  are expressed as mean ± SEM. Signiﬁcance, indicated by p < 0.05 wh
whether treatment and/or diet increased inﬂamma-
tory cytokine secretion, we measured the amount of
interleukin-6 (IL-6) in serum collected at euthana-
sia, Fig. 5. We  found circulating IL-6 was increased in
CD-BPA male and female mice, and in CD-DES males
Fig. 5. Serum IL-6, leptin and adiponectin analyses were measured in serum
mean  ± SEM. Signiﬁcance, indicated by p < 0.05 when compared with * VEH; † CDl Red O to identify adipocytes. Stained sections from male mice are shown
 n = 4 mice/group. VEH adipocyte area was artiﬁcially designated as 100%.
ared with * VEH.
when compared with CD-VEH mice. IL-6 was further
increased in HFD-DES males and females. Thus, BPA
and  DES exposure increased circulating IL-6 when fed
the  CD and IL-6 was further increased in HFD-DES
mice.
 collected at euthanasia from n = 5 mice/group. Data are expressed as
, ‡ males.
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To characterize adipokine secretion from fat, we  mea-
ured circulating leptin and adiponectin, Fig. 5. Leptin
evels usually reﬂect adiposity. Leptin was reduced in CD-
PA  and CD-DES males compared with CD-VEH males.
n  CD-fed females, there were no differences in leptin
evel among the treatment groups. HFD feeding induced
ncreased circulating leptin in male and female groups.
ithin the HFD-fed group, HFD-DES males had reduced
eptin compared with HFD-VEH males. Adiponectin levels
ere  higher in females than males, and were not altered
y  treatment or diet. Therefore, although BPA and DES
educed leptin levels when fed the CD, neither BPA nor DES
reatment  ablated or accentuated HFD-induced increases
n  circulating leptin.
.  Discussion
Greater BPA exposure in humans has been linked to an
ncreased risk for obesity and insulin resistance [10,44,45].
e  found that the BPA exposed C57bl/6n mice were larger
han  VEH mice at weaning and continued BPA exposure
ncreased adult prostate weight. These results are in agree-
ent  with an earlier study [38]. However, we found that
hronic  BPA exposure which began on GD11.5 and contin-
ed  until euthanasia of 4 months of age, did not contribute
o  greater body size in male or female mice. Further, this
hronic  BPA exposure did not induce greater insulin resis-
ance  in male or female mice fed a CD. Consistent with
arlier studies [46], HFD-VEH mice had more insulin resis-
ance  than those fed a CD and greater resistance was found
n  males than in females. This pattern was also present in
FD-BPA  male and female mice. HFD-DES males showed
ome  improved glucose tolerance over that of HFD-VEH
ice. Supporting the comparable GTT responses, total fat
eposition  and mesenteric fat adipocyte sizes were similar
n  VEH and BPA mice. DES mice with some improvement
n GTT also had less fat deposition and smaller mesen-
eric fat adipocytes. Despite the similar mesenteric fat
oads  in VEH and BPA mice, CD-BPA male and female mice
ad  increased IL-6, reduced leptin and similar adiponectin
rguing that some lipodystrophy was induced by chronic
PA  exposure. Based on our combined results, we  con-
lude  that neither chronic BPA exposure nor gestational
ES exposure substantially worsened the impact of obe-
ity  or obesity-induced glucose intolerance due to HFD
eeding  in males. Rather, we found chronic BPA and ges-
ational DES exposures induced an adipokine imbalance in
esponse  in mice fed the CD and sex speciﬁcally altered
he  lipid response and adipose deposition response to a
FD.
.1.  Chronic BPA exposure did not substantially change
lucose tolerance
Our  data support the argument that chronic oral BPA
xposure at a human relevant level, given either in
he  diet or in the drinking water, and in either out-
red or inbred mice, has little impact on adult male or
emale glucose tolerance which is in line with the results
f  earlier studies [16,20–22]. Our studies used inbred
57bl/6n mice with orally delivered BPA from GD11.5 toorts 1 (2014) 522–532 529
euthanasia  at 4 months. Similar to our study which used
C57bl/6n mice and at similar doses of BPA, GTT was  not
altered in CD-1 or Avy male or female mice exposed to oral
BPA  during gestation and lactation [16,20,21] or in CD-1
male  or female mice treated with BPA up to postnatal day
70  [22]. In contrast, subcutaneously injected BPA induced
glucose intolerance in male progeny of OF1 dams [17]
and  C57bl/6 dams [15]. Complicating direct comparison of
these  studies is the fact that dietary delivery and subcuta-
neous delivery of BPA may  not be equivalent. Although oral
and  subcutaneous injection of BPA led to increased prostate
weight  arguing some effectiveness of both delivery modes,
at  least for this activity [47], the physiological relevance
of subcutaneous injection for metabolic effects remains a
question,  especially given that most BPA exposure occurs
through the diet.
Besides  delivery route, the differing impacts of BPA on
glucose homeostasis may  also be inﬂuenced by dose and
the  exposure time relative to pancreatic and fat devel-
opment. Higher BPA doses given during gestation and
lactation have induced glucose intolerance in the adult
progeny [15–17,19]. Regarding the timing of BPA exposure
in  mice, the murine pancreas begins development around
GD  9–10 and has rudimentary insulin secreting abilities by
GD18,  and rapidly matures in the neonate [48]. Thus, ges-
tational  BPA exposure would be expected to have a greater
impact on early development of the pancreas and exposure
after  gestation would have more impact on later matu-
ration events. In contrast to exposure which is limited to
the  developmental period, chronic exposure has the poten-
tial  to modulate differentiation as well as maturation of
the  pancreas. Adult C57bl/6n males and females exposed
to  DES during GD11.5 to 14.5 in our experiments did not
develop  an increase in glucose intolerance whereas adult
CD-1  males treated with the similar dose from GD9-18
developed glucose intolerance [19]. The differing results
could  reﬂect either the sensitivity of the mouse strain or
the  more extended developmental period of DES expo-
sure  in the latter study. The differing outcomes in adults
of  chronic versus only early-life BPA exposures are con-
sistent  with the developmental origins of adult disease
hypothesis [49]. This hypothesis predicts that exposure to
BPA  in early life would drive increased disease susceptibil-
ity in the adult, whereas continued adult exposure would
not  be associated with any increased disease susceptibil-
ity.
The impact of BPA on glucose homeostasis is unlikely
to be inﬂuenced by the amount of fat in the diet. Glucose
tolerance was  similar in untreated mice and BPA exposed
mice  when they were fed control diets which were high
in  fat, such as the AIN93G diet [20–22] or low in fat such
as  the one used in our study or by Angle et al. [19]. To
the  best of our knowledge, two other studies have com-
bined  BPA exposure with a HFD. HFD feeding, whether at
weaning  as described here, or at 9 weeks of age [20] or
12  weeks of age [16] and a duration of either 12 weeks, 5
weeks  or 10 weeks, respectively, led to no change in glu-
cose  tolerance in mice exposed to low dose BPA. These data
suggest  that BPA exposure does not worsen the response
to  a glucose load when under a metabolic stress such as a
HFD.
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4.2. BPA modiﬁed circulating lipid levels, adipose tissue
deposition and adipocyte secretion
In CD-fed mice, BPA exposure increased serum choles-
terol in females, and reduced it in males, suggesting some
sex  speciﬁc impact. In contrast, no impact of low dose BPA
on  cholesterol or triglyceride was detected in CD-1 male
and  female mice fed the CD [22]. As expected, cholesterol
and triglyceride were increased by the HFD in VEH males
and  females, and were also increased by the HFD in BPA
and  DES males. Increases in cholesterol and triglyceride
were also found in Wistar rats fed a HFD after exposure to
BPA  during gestation and lactation [18]. These results sug-
gest  that gestational exposure to DES is sufﬁcient to modify
lipids  permanently. However, neither BPA nor DES expo-
sure  precluded an increase in circulating cholesterol and
triglyceride increase in males fed the HFD.
Our data indicate no increase in total fat accumulation
and suggest no increase in mesenteric adipocyte size after
chronic  BPA exposure. This result is similar to the lack of
increase  in body size and fat accumulation found in out-
bred  CD-1 or Avy mice exposed to low dose dietary BPA
[21,22]. Visceral obesity and increased glucose intolerance
are  risk factors for the metabolic syndrome. The lack of
increased total and mesenteric fat accumulation is in agree-
ment  with the lack of any increase in glucose intolerance in
BPA  or DES exposed mice. Together these data support the
idea  that chronic BPA exposure did not induce a metabolic
syndrome-like phenotype in C57bl/6n mice. Unlike visceral
or  mesenteric fat, increased ectopic fat surrounding organs
such  as the kidney or gonads is thought to contribute pri-
marily  to local toxic effects and not systemic metabolic
disease [50,51]. HFD feeding revealed sex-speciﬁc changes
in  ectopic fat deposition in BPA exposed mice. BPA expo-
sure  did not alter ectopic fat deposition surrounding the
testes  or kidneys in males. Rather, BPA exposure induced
increases in perirenal fat and reduced gonadal fat accu-
mulation in females compared with VEH females when
fed  the HFD. It is unclear whether these altered deposits
have any physiological impact on ovary function or renal
function in these mice. Increased perirenal fat is an indi-
cator  of impaired kidney function [52] suggesting that the
higher  amount of perirenal fat in HFD-BPA females might
prove  detrimental, and the lower amount in HFD-DES
males might be correlated with preserved kidney func-
tion.
Leptin  is produced in proportion to the amount of
body fat by mature adipocytes, especially those in visceral
fat  [53]. We found leptin was reduced in C57Bl/6n mice
exposed to BPA and DES and fed the CD. This result is in
contrast  to earlier studies which found increased leptin
in  BPA exposed OLF [17] and ICR mice [54]. No change in
leptin  level was detected in outbred CD-1 mice exposed
to  BPA (16). These data suggest that the mouse strain
used may  have a signiﬁcant effect on the ability of BPA
to  impact leptin secretion. We  measured circulating leptin
and  adiponectin after 12 weeks on the HFD. Thus, although
it  is likely that the changes in leptin and not adiponectin
levels are due to adaptations to the HFD and BPA, we
cannot comment on any hypothalamic signals that might
affect  feeding behavior because we did not measure foodorts 1 (2014) 522–532
consumption. Reduced leptin is associated with reduced
body fat and/or lipodystrophy [53]. The reduced leptin in
CD-BPA  and CD-DES males which had similar amounts of
total  body fat argues for some baseline lipodystrophy with
both  treatments. This is supported by the increase in cir-
culating IL-6 in BPA and DES exposed mice. IL-6, secreted
by  macrophages and adipocytes, is associated with low
grade  inﬂammation and the metabolic syndrome [55]. The
IL-6  increase in CD-BPA males and females supports the
idea  that BPA exposure induces a functional defect in fat
and  that this is also present in HFD-DES mice. Similar to
other  studies, leptin was increased in response to a pro-
tracted HFD and neither BPA nor DES exposure altered
this response [16,18,56]. Adiponectin is a key regulator
of insulin sensitivity [57]. Circulatory adiponectin levels
were  unaffected by BPA or DES exposure suggesting no
change  in insulin sensitivity. These data are consistent
with the lack of any substantial glucose intolerance in
the  BPA or DES exposed mice. Overall, the increased IL-
6,  reduced leptin and unchanged adiponectin suggest that
chronic  BPA exposure beginning in gestation and con-
tinuing into adulthood impairs fat function creating an
adipokine imbalance.
Thus,  our study shows evidence for chronic BPA expo-
sure  inducing sex-speciﬁc changes in serum cholesterol,
triglyceride, leptin and adiponectin as well as site-speciﬁc
fat accumulation which were also diet dependent. The
data  support the notion that chronic exposure to other
endocrine disrupting compounds might also inﬂuence
rodent, and potentially human, glucose homeostasis and
adipocyte function. There are many physiological differ-
ences  between mice and humans; however, our data
supports the idea that obesity and glucose control in
humans might be inﬂuenced by chronic exposure to
BPA,  and that this exposure may  increase metabolic dis-
ease.
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